Cingulate Inc.

CING | NASDAQ

Price Alert Chart Builder DCF Calculator

$5.23

-$0.01 (-0.19%)

At close: Sep 21, 2026, 4:00 PM ET

$5.27

+$0.04 (+0.75%)

After-hours: Sep 21, 2026, 7:30 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Overview Market Cap Employees

Company Profile

Cingulate Inc. is a biopharmaceutical enterprise currently in its clinical development phase, dedicated to devising therapeutic options for attention-deficit/hyperactivity disorder (ADHD). Leading its pipeline for ADHD are two drug candidates: CTx-1301 (dexmethylphenidate), which is currently progressing through Phase 3 clinical trials, and CTx-1302 (dextroamphetamine). The company is also engaged in the advancement of CTx-2103, a candidate intended for the management of anxiety disorders. Founded in 2012, Cingulate Inc. maintains its corporate headquarters in Kansas City, Kansas.

Key Executives

Name	Position
Shane J. Schaffer	Co-Founder, Chief Executive Officer & Chairman of the Board
Nilay Patel	Executive VP, Chief Legal Officer & Chief Compliance Officer
Downey Bryan Wade	Executive VP & Chief Commercial Officer
Jennifer L. Callahan	Executive VP, CFO & Secretary
Matthew N. Brams	Co-Founder, Executive Vice President & Chief Medical Officer
Raul R. Silva	Co-Founder, Executive Vice President & Chief Science Officer
Thomas Dalton	Vice President of Investor & Public Relations

Latest SEC Filings

Date	Type	Title
Aug 13, 2026	10-Q	Quarterly Report
Aug 13, 2026	8-K	Current Report
Jul 23, 2026	8-K	Current Report
Jul 20, 2026	4	Filing
Jul 20, 2026	4	Filing
Jul 20, 2026	4	Filing
Jul 20, 2026	4	Filing
Jul 20, 2026	4	Filing
Jul 20, 2026	4	Filing
Jul 20, 2026	4	Filing

View All SEC Filings ➞

Cingulate Inc.

Country	United States
IPO Date	Dec 7, 2021
Industry	Biotechnology
Sector	Healthcare
Employees	14
CEO	Shane J. Schaffer

Contact Details

1901 West 47th Place Kansas City, Kansas 66205 United States

https://www.cingulate.com

913 942 2300

Stock Details

Ticker Symbol	CING
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001862150
CUSIP Number	17248W303
ISIN Number	US17248W3034
SIC Code	2834